The ability of CADs to potently inhibit the transcriptional activity of STAT3 is of particular interest because the strong clinical applicability and the repurposing potential of cationic amphiphilic antihistamines for cancer therapy might circumvent the dilemma that none of the conventional STAT3 inhibitors have passed stringent clinical trials. This evidence concerns the gene STAT3 and cancer.